Joseph J. Ferra Jr - May 15, 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Robert Yang, Attorney-in-Fact
Stock symbol
ELEV
Transactions as of
May 15, 2025
Transactions value $
-$690
Form type
4
Date filed
5/19/2025, 04:10 PM
Previous filing
Mar 18, 2025
Next filing
Jun 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ferra Joseph J Jr CHIEF EXECUTIVE OFFICER, Director C/O ELEVATION ONCOLOGY, INC., 101 FEDERAL STREET, SUITE 1900, BOSTON /s/ Robert Yang, Attorney-in-Fact 2025-05-19 0001733790

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +6.25K +4.69% 139K May 15, 2025 Direct F1
transaction ELEV Common Stock Tax liability -$690 -2.3K -1.65% $0.30 137K May 15, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -6.25K -8.33% $0.00 68.8K May 15, 2025 Common Stock 6.25K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.